fosamax femur fracture lawsuit
Patients and healthcare professionals may have concerns about oral bisphosphonate medications and atypical subtrochanteric femur fractures &ndash fractures in the bone just beneath the hip joint. Oral bisphosphonates are generally prescribed to avoid or treat osteoporosis in postmenopausal ladies. Widespread brand names of medicines in this class include Fosamax, Actonel, Boniva, and Reclast. If you have taken fosamax you should speak to your health care provider to see if you are at risk for a fosamax femur fracture.
Recent news reports have raised the question about regardless of whether there is an improved threat of this sort of fracture in patients with osteoporosis making use of these medicines. At this point, the data that FDA has reviewed have not shown a clear connection among bisphosphonate use and a threat of atypical subtrochanteric femur fractures. FDA is working closely with outside specialists, which includes members of the not too long ago convened American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force, to collect extra info that might provide a lot more insight into this issue.
Based on published case reports of atypical subtrochanteric femur fractures occurring in ladies with osteoporosis making use of bisphosphonates, FDA, in June 2008, requested information from all bisphosphonate drug manufacturers with regards to this prospective safety signal. All obtainable case reports and clinical trial data had been requested. FDA’s assessment of these data did not show an improve in this danger in women employing these medicines.
In addition, FDA reviewed a December 2008 write-up in the Journal of Bone and Mineral Investigation by Abrahamsen et al1, that analyzed data from two huge observational studies in patients with osteoporosis. The authors concluded that atypical subtrochanteric femur fractures had several similar features in common with classical osteoporotic hip fractures, including patient age, gender, and trauma mechanism. The data showed that patients taking bisphosphonates and those not taking bisphosphonates had similar numbers of atypical subtrochanteric femur fractures relative to classical osteoporotic hip fractures. If you or someone you know has suffered a femur fracture after taking Fosamax, you or they may be eligible for a fosamax femur fracture lawsuit.
This communication is in keeping with FDA’s commitment to inform the public about its ongoing safety evaluation of drugs. The agency will continue to assessment new information as it becomes accessible and will update the public as soon as the agency’s review is full.
Healthcare pros ought to continue to adhere to the recommendations in the drug label when prescribing oral bisphosphonates. Patients should not cease taking their medication unless told to do so by their healthcare skilled. Patients ought to speak to their healthcare professional about any concerns they have with these medications.